Private Advisor Group LLC Increases Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Private Advisor Group LLC grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,127 shares of the medical research company’s stock after buying an additional 271 shares during the period. Private Advisor Group LLC’s holdings in Thermo Fisher Scientific were worth $13,686,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TMO. Westhampton Capital LLC boosted its position in shares of Thermo Fisher Scientific by 1.4% in the 3rd quarter. Westhampton Capital LLC now owns 2,217 shares of the medical research company’s stock valued at $1,371,000 after purchasing an additional 30 shares during the period. Symphony Financial Ltd. Co. boosted its holdings in shares of Thermo Fisher Scientific by 142.9% in the third quarter. Symphony Financial Ltd. Co. now owns 1,394 shares of the medical research company’s stock valued at $856,000 after acquiring an additional 820 shares during the period. Eastern Bank increased its position in Thermo Fisher Scientific by 20.2% in the 3rd quarter. Eastern Bank now owns 32,228 shares of the medical research company’s stock valued at $19,935,000 after acquiring an additional 5,410 shares during the period. Signaturefd LLC raised its stake in Thermo Fisher Scientific by 1.1% during the 3rd quarter. Signaturefd LLC now owns 8,571 shares of the medical research company’s stock valued at $5,302,000 after acquiring an additional 96 shares during the last quarter. Finally, Sequoia Financial Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 5.8% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 89,268 shares of the medical research company’s stock valued at $55,218,000 after purchasing an additional 4,879 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently weighed in on TMO. UBS Group raised Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Robert W. Baird raised their target price on Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Wells Fargo & Company assumed coverage on Thermo Fisher Scientific in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $670.00 price target for the company. JPMorgan Chase & Co. raised their price target on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a research report on Friday, September 20th. Finally, Evercore ISI boosted their price objective on shares of Thermo Fisher Scientific from $605.00 to $630.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $655.50.

Thermo Fisher Scientific Trading Down 1.7 %

Shares of NYSE:TMO opened at $576.49 on Thursday. The stock has a market capitalization of $220.06 billion, a price-to-earnings ratio of 36.98, a PEG ratio of 3.85 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $627.88. The company has a 50 day moving average price of $607.04 and a 200 day moving average price of $584.39. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The business had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.50 billion. During the same period in the previous year, the firm posted $5.15 EPS. The company’s quarterly revenue was down 1.4% on a year-over-year basis. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 860 shares of the firm’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $611.03, for a total value of $525,485.80. Following the completion of the transaction, the chief accounting officer now directly owns 1,814 shares in the company, valued at $1,108,408.42. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, CAO Joseph R. Holmes sold 860 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $611.03, for a total value of $525,485.80. Following the completion of the sale, the chief accounting officer now owns 1,814 shares in the company, valued at $1,108,408.42. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Lisa P. Britt sold 3,624 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 26th. The shares were sold at an average price of $613.02, for a total value of $2,221,584.48. Following the transaction, the vice president now owns 13,699 shares in the company, valued at $8,397,760.98. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 23,084 shares of company stock valued at $14,094,292. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.